Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.

In 30 seconds

This systematic review and frequentist network meta-analysis compared lipid-modifying therapies in people with diabetes, using evidence from 18 randomised controlled trials involving 89,717 participants. Statins, ezetimibe, PCSK9 inhibitors and bempedoic acid were each associated with reduced major adverse cardiovascular events (MACE), with differences across agents and outcomes. Atorvastatin was associated with reductions in several cardiovascular outcomes; moderate- and high-dose atorvastatin reduced revascularization risk, while pravastatin was associated with a marked reduction in stroke risk. Ezetimibe and evolocumab were associated with lower myocardial infarction risk.

Key findings

• Across 18 trials and 89,717 participants, statins, ezetimibe, PCSK9 inhibitors and bempedoic acid were each associated with reduced MACE.
• Atorvastatin at moderate and high doses was associated with reduced revascularization risk; pravastatin was associated with a marked reduction in stroke risk.
• Ezetimibe and evolocumab showed comparable efficacy and were associated with reduced myocardial infarction risk.
• PCSK9 inhibitors improved total and LDL cholesterol, while pemafibrate had pronounced triglyceride-lowering efficacy.

Why it matters

The analysis suggests that lipid-modifying therapies may differ in their cardiovascular and lipid effects in people with diabetes, rather than offering interchangeable benefits across all outcomes. This agent- and dose-level comparison can help frame treatment discussions around the outcome of interest, while also drawing attention to safety signals the authors identify for monitoring.

What to keep in mind

The findings are based on a network meta-analysis of 18 trials; comparisons across agents and doses may therefore rely on indirect evidence. The abstract does not report effect estimates or certainty ratings.